BRI3BP and neoplasm: BRI3BP expression correlated strongly with immunosuppressive subsets—Th2 cells (r = 0.482, P < 0.001) and CD4 + T cells (r = 0.208, P = 1.00e-04), indicating that BRI3BP may foster an immunosuppressive tumor microenvironment linked to resistance to immune-checkpoint blockade in HCC35.